Drug Discovery
Pipeline
Drug Discovery aims to develop pipeline of transformative medicines
Indication
Discovery
Preclinical
IND-Ready
Clinical
Partner
TCR
Therapeutics
Indication
Oncology1
Discovery
Preclinical
IND-Ready
Clinical
First shared cell therapy
Second shared cell therapy
Personalized cell therapy
Partner
Indication
Autoimmune
Diseases
Discovery
Preclinical
IND-Ready
Clinical
TCR-Treg
Antibody
Therapeutics
Indication
Infectious
Diseases
Discovery
Preclinical
IND-Ready
Clinical
SARS-CoV-2
Influenza A
RSV
1 Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The first shared and second shared cell therapy product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to, the FDA.